FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’snews2024-07-02T18:58:44+00:00July 2nd, 2024|The New York Times|
FDA Advisory Panel Endorses Approval of Alzheimer’s Drug Made by Eli Lillynews2024-06-10T21:05:19+00:00June 10th, 2024|The New York Times|
Trump’s Takeover of the Republican Partynews2024-02-15T17:38:23+00:00February 15th, 2024|The New York Times|
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelmnews2024-01-31T19:10:58+00:00January 31st, 2024|The New York Times|
FDA Approves First Pill for Postpartum Depressionnews2023-08-05T03:39:10+00:00August 5th, 2023|The New York Times|
FDA Makes Alzheimer’s Drug Leqembi Widely Accessiblenews2023-07-06T21:26:16+00:00July 6th, 2023|The New York Times|
FDA Approves Biogen’s Drug for Rare Form of ALSnews2023-04-25T17:53:59+00:00April 25th, 2023|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
Alzheimer’s Drug May Benefit Some Patients, New Data Showsnews2022-11-30T00:50:06+00:00November 30th, 2022|The New York Times|
